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ABSTRACT 
 
Background: Conversation is the archetypal mode of communication. As a process it draws on numerous skills, 
and predispositions, adapting to dynamic contexts and coordinated in highly sophisticated ways for successful 
interaction. The combination of these abilities with contextual variables coalesces uniquely to represent what this 
research proposes to be conversational intelligence. It is argued here that high levels of conversational 
intelligence rest to a large degree on executive functions (EF) which are steadily becoming more widely 
acknowledged and researched within the communication domain. The impairment of EF in neurologically 
injured individuals has significant, though as yet undisclosed, repercussions for recovery, response to therapy 
and ability to integrate communication skills in every day interactions to support conversational success. This 
study incorporates some new approaches to the study of communication disorders following stroke, including 
conversation, executive functions and the possibility of pharmacological intervention.  
 
Aims: The aims of this study were to describe in detail the language, executive function and conversational 
characteristics of ten individuals who had experienced strokes and to examine the relationships among these 
three areas of functioning. In addition, this research investigated the response of these ten participants to 
pharmacological therapy on a one month trial of Leviteracetam (LEV).  
 
Methods and Procedures: Ten individuals who had suffered single incident strokes were recruited from local 
community and rehabilitation facility referrals. All ten participated in a four stage randomised, double blind 
investigation including baseline, active, placebo and withdrawal phases. At each stage participants underwent 
testing on an EF battery and were recorded having conversations with familiar interlocutors. In addition, 
significant others completed a rating scale assessing affective features and behaviours and language testing was 
conducted at the baseline phase using the WAB. The language and EF data were scored and the conversations 
subjected to Conversation Analysis. For each participant, profiles were created and assessed for inter-
relationships between the executive characteristics and conversational features representative of each executive 
construct. Repeated measures analysis of variance was conducted on EF data for the four phases of the study to 
determine significant pharmacological effects.  
 
Outcomes and Results: The majority of the sample presented with significant EF deficits across most areas 
assessed. Two participants presented with essentially intact profiles which were not explained in terms of types 
of aphasia or site of lesion. Language results proved to be inconsistently associated with EF deficits, but 
conversational features reflected underlying executive strengths or deficits with greater consistency. Two 
participants experienced amelioration (though not statistically significant) of interference control during the 
active phase, with observable improvements in conversational skill. One participant demonstrated improved 
conversation without a change in EF scores. The response to LEV is evaluated with reference to potential 
alternatives.  
 
Conclusions: The existence of EF deficits in individuals with stroke is demonstrated. Furthermore, the impact of 
these impairments is considerable and observable during naturally occurring conversations, suggesting the 
centrality of the EF contribution to conversational intelligence. The lack of association between formal language 
test scores and EF impairments argues for the inclusion of more authentic assessment approaches for stroke 
patients. The data is explored in terms of specific consequences of different lesion sites on EF and 
communication and briefly addresses bilingualism as a potential variable in explaining some of the variations in 
the data. Pharmacotherapy is addressed as an important focus of future research protocols. Implications for 
assessment and treatment are discussed as well as proposals for future study. 
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A NOTE ON ANONYMITY 
 
When the participants were approached about taking part in this study, they were told that their 
identities would be protected and that they were entitled to anonymity. Two stated that they would be 
happy to choose pseudonyms for the purposes of the presentation of the results. One stated that it made 
no difference one way or the other. The other seven not only said that they would have no reservations 
about their own names being used but specifically requested that they be named. When asked why, they 
unanimously said that their strokes have to a greater or lesser extent effectively removed them from the 
public eye. They have been transformed into people who inhabit private and unarticulated lives despite 
the fact that they want to be heard, want to be “useful” and want “a voice”. The participants have 
reserved the right to claim ownership of their contributions. Eight of them are therefore deliberately 
named: Cecil, Felicity, Grace, Jeannette, John, Mel, Margaret and Tumi. Jane* and Paul* chose instead 
to be identified by pseudonyms.  
 
In the conversational transcripts, all participants are identified by their initials. When the researcher is 
the interlocutor, she is represented by the letter R. Friends, family members or spouses are also 
identified by initials and are acknowledged in the text.  
